Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Current Deferred Revenue (2016 - 2026)

Integra Lifesciences Holdings' Current Deferred Revenue history spans 17 years, with the latest figure at $23.0 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 16.99% to $23.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.0 million, a 16.99% increase, with the full-year FY2025 number at $23.0 million, up 16.99% from a year prior.
  • Current Deferred Revenue hit $23.0 million in Q4 2025 for Integra Lifesciences Holdings, up from $22.3 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for IART hit a ceiling of $23.0 million in Q4 2025 and a floor of $5.3 million in Q1 2022.
  • Historically, Current Deferred Revenue has averaged $11.9 million across 5 years, with a median of $10.8 million in 2025.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 54.97% in 2022 and later surged 209.92% in 2023.
  • Tracing IART's Current Deferred Revenue over 5 years: stood at $11.9 million in 2021, then tumbled by 39.29% to $7.3 million in 2022, then surged by 124.07% to $16.3 million in 2023, then grew by 21.03% to $19.7 million in 2024, then rose by 16.99% to $23.0 million in 2025.
  • Business Quant data shows Current Deferred Revenue for IART at $23.0 million in Q4 2025, $22.3 million in Q3 2025, and $11.1 million in Q2 2025.